A Study to Evaluate the Efficacy and Safety of Polatuzumab Vedotin in Combination With Bendamustine and Rituximab Compared With Bendamustine and Rituximab Alone in Chinese Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL).

Condition:   Diffuse, Large B-Cell, Lymphoma Interventions:   Drug: Polatuzumab Vedotin;   Drug: Bendamustine;   Drug: Rituximab;   Drug: Placebo Sponsor:   Hoffmann-La Roche Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials